BDNF Gene Polymorphism and Antidepressants Treatment
The main hypothesis is that the therapeutic response and pharmacological resistance to ADs in depressed patients can be associated with a polymorphism for the BDNF gene. The research of allelic forms associated to lesser efficiency or inefficiency of ADs could add to the body of evidence that BDNF mediates the mechanism of action of ADs, and could have important practical implications. We propose to compare in a group of patients with major depression, the allelic variability of the BDNF gene between responders and non-responders after a 3-week period and a 6-week period of SSRI treatment.
|Study Design:||Endpoint Classification: Pharmacodynamics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Brain Derived Neurotrophic Factor (BDNF) Gene Polymorphism and Response to Antidepressants Treatment in Major Depression|
- Score on Montgomery and Asberg Depression Rating Scale (MADRS) [ Time Frame: At 3 weeks and 6 weeks ] [ Designated as safety issue: No ]
|Study Start Date:||July 2006|
|Study Completion Date:||June 2012|
|Primary Completion Date:||June 2012 (Final data collection date for primary outcome measure)|
Treatment response after 3 and 6 weeks
Genetic: Genetic analysis
Compare BDNF polymorphism among responders and non-responders
- The main objective is to research an association between polymorphism for the BDNF gene and the 3-week and 6-week response to a SSRI treatment (escitalopram) in major depression.
- A case control pilot study without any direct individual benefit (200 patients).
- Study period: 24 months.
- Scores from reliable and validated psychometric scales (Montgomery and Asberg Depression Scale, Mini International Neuropsychiatric Interview) specifically analysing depression dimension at the time of inclusion, after three and six weeks of antidepressant treatment.
- Genetic analysis researching a polymorphism of the BDNF gene is done by a blood sample at the baseline.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00308893
|CPU CHRU de Tours|
|Tours, France, 37044|
|Principal Investigator:||Wissam EL HAGE, MD, PhD||UNIVERSITY HOSPITAL OF TOURS|